Abstract
To the Editor: We read with interest the recent article by Miao et al,1 which presents the results of a post hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Study. The results suggest that losartan reduces serum uric acid (sUA), and this relates to the degree of long-term renal risk reduction and explains part of losartan's renoprotective effect. We raise some issues. sUA remained at its baseline of 6.7 mg/dL after losartan treatment. Because the placebo arm showed a rise in sUA (6.7–6.9 mg/dL), there was a mean group difference in sUA of …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.